Difficult Burden: Did Ariad v. Lilly Strike the Right Balance for Incentivizing Emerging Technologies?

April 29, 2010

N. Scott Pierce will be speking at the Boston Patent Law Association (BPLA) program on how the recent Federal Circuit decision in Ariad settles the long and heated debate whether the written description requirement is a misreading of the patent statute. The Court arguably appears unsympathetic to universities, small biotechnology companies, and other emerging enterprises in need of adequate protection for their inventions. What are the practical implications of this decision on the academic institutions and the biotechnology industry?

Join the esteemed panel of speakers for a lively discussion of the Ariad decision and its impact.

About

April 29, 2010

N. Scott Pierce will be speking at the Boston Patent Law Association (BPLA) program on how the recent Federal Circuit decision in Ariad settles the long and heated debate whether the written description requirement is a misreading of the patent statute. The Court arguably appears unsympathetic to universities, small biotechnology companies, and other emerging enterprises in need of adequate protection for their inventions. What are the practical implications of this decision on the academic institutions and the biotechnology industry?

Join the esteemed panel of speakers for a lively discussion of the Ariad decision and its impact.

Back to the Top